NCT02912897View on ClinicalTrials.gov

Trial to Assess the Safety and Feasibility of Adoptive Cell Therapy with Autologous EBV-specific Cytotoxic T Lymphocytes (CTL) in Patients with a First Clinical Episode Highly Suggestive of Multiple Sclerosis

PHASE1RecruitingINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

January 26, 2021

Primary Completion Date

November 30, 2028

Study Completion Date

November 30, 2028

Conditions
Multiple Sclerosis
Interventions
BIOLOGICAL

Cellular therapy with EBV specific autologous CTL infusion

CTL infusions at D0, M3 and M6

Trial Locations (1)

Unknown

RECRUITING

University Hospital, Nantes

All Listed Sponsors
lead

Nantes University Hospital

OTHER